Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) are up more than 40% in the last 12 months, and lately all eyes have been on its experimental Morquio syndrome drug. However, today the orphan drugmaker announced a $10 million deal to acquire Zacharon PharmaceuticalsIn this video, our health care analyst discusses this news and touches on last year's success of some prominent orphan drug companies, including NPS Pharmaceuticals (NASDAQ:NPSP) and Sarepta (NASDAQ:SRPT).

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.